Too early in the launch to critque. I sure hope they plan on some direct to consumer advertising and don't rely solely on the reps. There are a lot of prospective patients that don't frequent a GI specialist on a regular basis, if at all. Some advertising would probably help the stock as well.
If the drug sales go well,the short position should finally dissipate. A hostile takeover might be in order if sales lag Linzess badly. Shame we don't know if there has been interest in partnership or buyout.
News 
Market Data 
Discover 
